The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro

April 4, 2020 at 9:23 pm

 Antiviral Research April 3, 2020

Highlights

  • Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.
  • A single treatment able to effect ∼5000-fold reduction in virus at 48h in cell culture.
  • Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.
  • Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines.

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

FULL TEXT

https://www.sciencedirect.com/science/article/pii/S0166354220302011

PDF (CLIC en DOWNLOAD PDF)

Entry filed under: Antiparasitarios, Biología Molecular, Epidemiología, Infecciones emergentes, Infecciones respiratorias, Infecciones virales, Metodos diagnosticos, REPORTS, Sepsis, Update.

NEWS – Covid-19 – US gives emergency approval to hidroxichloroquine despite lack of evidence Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.


Calendar

April 2020
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
27282930  

Most Recent Posts


%d bloggers like this: